Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genelux Corporation

4.09
+0.17004.34%
Post-market: 4.090.00000.00%16:10 EDT
Volume:289.72K
Turnover:1.15M
Market Cap:154.49M
PE:-4.77
High:4.14
Open:3.93
Low:3.76
Close:3.92
52wk High:5.89
52wk Low:1.95
Shares:37.77M
Float Shares:33.74M
Volume Ratio:2.05
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8568
EPS(LYR):-0.9497
ROE:-98.72%
ROA:-52.14%
PB:6.46
PE(LYR):-4.31

Loading ...

Company Profile

Company Name:
Genelux Corporation
Exchange:
NASDAQ
Establishment Date:
2001
Employees:
24
Office Location:
2625 Townsgate Road,Suite 230,Westlake Village,California,United States
Zip Code:
91361
Fax:
- -
Introduction:
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Directors

Name
Position
Thomas Zindrick
President, Chief Executive Officer and Chairman
James L. Tyree
Lead Independent Director
John Smither
Director
John Thomas
Director
Mary Mirabelli
Director

Shareholders

Name
Position
Thomas Zindrick
President, Chief Executive Officer and Chairman
Matthew Pulisic
Chief Financial Officer
Tony Yu
Senior Vice President, Clinical Development
Eric Groen
General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Joseph Cappello
Chief Technical Officer
Paul Scigalla
Chief Medical Officer
Ralph Smalling
Head of Regulatory